ERESEARCHTECHNOLOGY UPDATES 3RD QTR/FULL YEAR OUTLOOK.

eResearchTechnology, Inc. (eRT), (NASDAQ:ERES), Philadelphia, a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, has updated its outlook for the third quarter ended September 30, 2004 and year ending December 31, 2004.

eRT expects revenue in the third quarter to grow between 55% and 60% year over year with revenues between $27.0 million and $28.0 million and earnings per diluted share to grow between 85% and 100% year over year to $0.13 to $0.14, compared to the company's previous guidance of $30.0 million to $30.5 million in revenues and earnings per diluted share of $0.16 to $0.17. The company expects revenues for the full year to grow between 68% and 72% year over year with revenues between $112.0 million and $115.0 million and earnings per diluted share to grow between 115% and 122% year over year to $0.58 to $0.60, compared to company's previous guidance of $117.0 million to $119.0 million in revenues and earnings per diluted share of $0.62 to $0.63.

The third quarter results were impacted by delays in Thorough Phase I studies, with a transaction value of approximately $3.0 million, due to weather, inadequate patient enrollment and late stage protocol amendments consistent with regulatory guidance updates. eRT anticipates that these studies will be completed in the fourth quarter. In addition, targeted one- time technology sales were not consummated by end of the third quarter as the company had anticipated. The company's fourth quarter and year-end outlook reflect the impact of delays in receiving three new Thorough Phase I signings in the third quarter that the company had previously anticipated. The combination of a historically slower period for new signings, in addition to sponsor review of recent updates to regulatory guidance, likely contributed to these signing delays, which the company will target to consummate in the fourth quarter.

Based in Philadelphia, PA, eResearchTechnology, Inc. is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core- diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.

For more information, call 215/282-5580 or call http://www.ert.com.